Therapeutic drug monitoring (TDM) of elexacaftor, tezacaftor, ivacaftor (ETI) could be a useful tool to increase efficacy and decrease the risk of adverse effects in people with Cystic Fibrosis (pwCF). It is however unclear whether drug exposure should be monitored by assessment of trough (C) levels or determination of the area under the curve (AUC). Hence, in this study the correlation between measured C concentration and AUC was evaluated. Serial plasma samples, including C, were drawn after administration of ETI in order to calculate the AUC and assess the correlation between the two parameters. A linear correlation between C and AUC was found, with Pearson's correlation coefficients of 0.963, 0.908 and 0.860 for elexacaftor, tezacaftor and ivacaftor, respectively. Exposure of ETI may be monitored by assessment of C levels.

中文翻译：

---

elexacaftor、tezacaftor 和 ivacaftor 的谷浓度与 AUC 之间的相关性

elexacaftor、tezacaftor、ivacaftor (ETI) 的治疗药物监测 (TDM) 可能是提高囊性纤维化 (pwCF) 患者疗效并降低不良反应风险的有用工具。然而，尚不清楚是否应通过评估谷值 (C) 水平或确定曲线下面积 (AUC) 来监测药物暴露。因此，在本研究中评估了测量的 C 浓度和 AUC 之间的相关性。 ETI 给药后抽取系列血浆样本（包括 C），以计算 AUC 并评估两个参数之间的相关性。发现 C 和 AUC 之间存在线性相关性，elexacaftor、tezacaftor 和 ivacaftor 的 Pearson 相关系数分别为 0.963、0.908 和 0.860。 ETI 的暴露可以通过评估 C 水平来监测。